Abstract:Ethnopharmacological relevance Zexie-Baizhu Decoction (AA), a Chinese Classical Formula composed of Alisma orientalis (Sam.) Juzep . and Aractylodes Macrocephala Koidz in the specific ratio of 5:2, has a long history of use in treating metabolic disorders. Recent studies have demonstrated AA's ameliorative effects on non-alcoholic fatty liver disease (NAFLD); however, the mechanism underlying its action on the gut and adipose tissue, key regulators of metabolism, have not been fully explored. Aim of the study This study aimed to investigate the mechanisms by which AA regulates the homeostasis of gut and adipose tissue in NAFLD. Materials and Methods AA (1500 mg/kg/day) or vehicle was administrated to the high-fat diet-induced and normal chow-fed mice (C57BL/6J). Plasma, the liver, gut microbiota, bile acids, and short-chain fatty acids in the gut, were systematically investigated. RNA sequencing analysis, reverse transcription quantitative real-time PCR, and Western Blotting were performed on the epididymal white adipose tissues (eWAT) to explore AA's influence on NAFLD. Lipidomics of the liver and eWAT were analyzed by liquid chromatography-mass spectrometry and desorption electrospray ionization mass spectrometry imaging. Results Our study demonstrated that AA administration effectively alleviated liver injury induced by NAFLD, as evidenced by reduced hepatic fat accumulation and inflammation. Mechanistically, AA modulated the composition of the gut microbiota, promoting the growth of beneficial bacteria such as Akkermansia muciniphila and restoring the balance between Firmicutes and Bacteroidetes. Furthermore, AA regulated the levels of bile acids and short-chain fatty acids in the intestine, plasma, and liver. Correspondingly in the eWAT, AA administration activated bile acid receptor ( Gpbar1 ) and short-chain fatty acid receptor ( Ffar2 ), facilitating lipid breakdown and attenuating triglyceride accumulation. Transcriptome analysis revealed that AA influenced gene expression related to fatty acid metabolism, thermogenesis, insulin resistance, AMPK signaling, and the tricarboxylic acid (TCA) cycle, thereby improving NAFLD at the transcriptional level. Additionally, AA treatment significantly altered the lipid composition in the liver, reducing levels of diacylglycerols, triacylglycerols, phosphatidylserines, and cholesterol esters, while increasing levels of phosphatidic acids, phosphatidylethanolamines, and sphingomyelins. Conclusion Our study builds a connection between the gut and adipose tissue to understand the mechanism of AA on alleviating NAFLD, providing new insights into the development of targeted therapies for this condition.

Astaxanthin Alleviates Nonalcoholic Fatty Liver Disease by Regulating the Intestinal Flora and Targeting the AMPK/Nrf2 Signal Axis

Astaxanthin Attenuates Hepatic Damages and Mitochondrial Dysfunction in Nonalcoholic Fatty Liver Disease by Regulating the FGF21/PGC-1α Pathway

Astaxanthin attenuates hepatic damage and mitochondrial dysfunction in non‐alcoholic fatty liver disease by up‐regulating the FGF21/PGC‐1α pathway

Atractylenolide III ameliorates Non-Alcoholic Fatty Liver Disease by activating Hepatic Adiponectin Receptor 1-Mediated AMPK Pathway

Allyl Isothiocyanate Ameliorates Lipid Accumulation and Inflammation in Nonalcoholic Fatty Liver Disease Via the Sirt1/AMPK and NF-κB Signaling Pathways.

Fucoxanthin Attenuates Free Fatty Acid-Induced Nonalcoholic Fatty Liver Disease by Regulating Lipid Metabolism/Oxidative Stress/Inflammation via the AMPK/Nrf2/TLR4 Signaling Pathway

Astaxanthin Prevents Alcoholic Fatty Liver Disease by Modulating Mouse Gut Microbiota.

Astaxanthin From Haematococcus pluvialis Prevents High-Fat Diet-Induced Hepatic Steatosis and Oxidative Stress in Mice by Gut-Liver Axis Modulating Properties

Hepatic parenchymal cell and mitochondrial-targeted astaxanthin nanocarriers for relief of high fat diet-induced nonalcoholic fatty liver disease

PROTECTION OF ASTAXANTHIN AGAINST HIGH-FAT DIET-INDUCED NON-ALCOHOLIC FATTY LIVER DISEASE IN MICE

Astaxanthin Prevents Diet-Induced NASH Progression by Shaping Intrahepatic Immunity

Preventative and Therapeutic Effects of Astaxanthin on NAFLD

Asperuloside Alleviates Lipid Accumulation and Inflammation in HFD-induced NAFLD Via AMPK Signaling Pathway and NLRP3 Inflammasome

Arjunolic Acid from Cyclocarya Paliurus Ameliorates Nonalcoholic Fatty Liver Disease in Mice Via Activating Sirt1/AMPK, Triggering Autophagy and Improving Gut Barrier Function

Agastache rugosa alleviates the multi-hit effect on hepatic lipid metabolism, inflammation and oxidative stress during nonalcoholic fatty liver disease

Astaxanthin inhibits inflammation and fibrosis in the liver and adipose tissue of mouse models of diet-induced obesity and nonalcoholic steatohepatitis

Apigenin ameliorates HFD-induced NAFLD through regulation of the XO/NLRP3 pathways

Mechanisms of Protective Effects of Astaxanthin in Nonalcoholic Fatty Liver Disease

5-ALA Ameliorates Hepatic Steatosis Through AMPK Signaling Pathway

Acanthoic Acid Modulates Lipogenesis in Nonalcoholic Fatty Liver Disease Via FXR/LXRs-dependent Manner

Zexie-Baizhu Decoction ameliorates non-alcoholic fatty liver disease through gut-adipose tissue crosstalk